Characteristics of Patients With <15% Reduction in Low-Density Lipoprotein Cholesterol With Alirocumab

被引：0
|
作者：
Bays, Harold E.
Rosenson, Robert S.
Baccara-Dinet, Marie T.
Louie, Michael J.
Thompson, Desmond E.
Hovingh, G. Kees
机构：
来源：
CIRCULATION | 2017年 / 136卷
关键词：
Hyperlipidemia; LDL; Cholesterol; Cholesterol-lowering drugs; PCSK9;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
15726
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Alirocumab for low-density lipoprotein cholesterol lowering
    Roth, Eli M.
    FUTURE CARDIOLOGY, 2019, 15 (01) : 17 - 29
  • [2] Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab Trials
    Bays, Harold E.
    Rosenson, Robert S.
    Baccara-Dinet, Marie T.
    Louie, Michael J.
    Thompson, Desmond
    Hovingh, G. Kees
    CARDIOVASCULAR DRUGS AND THERAPY, 2018, 32 (02) : 175 - 180
  • [3] Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab Trials
    Harold E. Bays
    Robert S. Rosenson
    Marie T. Baccara-Dinet
    Michael J. Louie
    Desmond Thompson
    G. Kees Hovingh
    Cardiovascular Drugs and Therapy, 2018, 32 : 175 - 180
  • [4] The Future of Low-Density Lipoprotein Cholesterol in an Era of Nonfasting Lipid Testing and Potent Low-Density Lipoprotein Lowering
    Farukhi, Zareen
    Mora, Samia
    CIRCULATION, 2018, 137 (01) : 20 - 23
  • [5] Comparison of Low-density Lipoprotein Cholesterol Threshold Attainment With Alirocumab versus Ezetimibe Treatment in the ODYSSEY Program
    Cannon, Christopher P.
    Cariou, Bertrand
    Valcheva, Velichka
    Guillonneau, Sophie
    Iorga, Serban R.
    Davidson, Michael H.
    CIRCULATION, 2016, 134
  • [6] Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction
    Henry, Courtney A.
    Lyon, Ronald A.
    Ling, Hua
    VASCULAR HEALTH AND RISK MANAGEMENT, 2016, 12 : 163 - 169
  • [7] Attainment of low-density lipoprotein cholesterol goals in coronary artery disease
    Kauffman, Amy B.
    Olson, Kari L.
    Youngblood, Morgan L.
    Zadvorny, Emily B.
    Delate, Thomas
    Merenich, John A.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2010, 4 (03) : 173 - 180
  • [8] Effect of Pelacarsen on Lipoprotein(a) Cholesterol and Corrected Low-Density Lipoprotein Cholesterol
    Yeang, Calvin
    Karwatowska-Prokopczuk, Ewa
    Su, Fei
    Dinh, Brian
    Xia, Shuting
    Witztum, Joseph L.
    Tsimikas, Sotirios
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 79 (11) : 1035 - 1046
  • [9] Prevalence and characteristics of patients with low levels of low-density lipoprotein cholesterol in northern Denmark: a descriptive study
    Schmidt, Sigrun Alba Johannesdottir
    Heide-Jorgensen, Uffe
    Manthripragada, Angelika D.
    Ehrenstein, Vera
    CLINICAL EPIDEMIOLOGY, 2015, 7 : 201 - 211
  • [10] Ablation of Plasma Prekallikrein Decreases Low-Density Lipoprotein Cholesterol by Stabilizing Low-Density Lipoprotein Receptor and Protects Against Atherosclerosis
    Wang, Jin-Kai
    Li, Yang
    Zhao, Xiao-Lu
    Liu, Yuan-Bin
    Tan, Jing
    Xing, Yu-Ying
    Adi, Dilare
    Wang, Yong-Tao
    Fu, Zhen-Yan
    Ma, Yi-Tong
    Liu, Song-Mei
    Liu, Yong
    Wang, Yan
    Shi, Xiong-Jie
    Lu, Xiao-Yi
    Song, Bao-Liang
    Luo, Jie
    CIRCULATION, 2022, 145 (09) : 675 - 687
12345